Prevalence of Prediabetes Among Adolescents and Young Adults in the United States, 2005-2016
Individuals with prediabetes are at increased risk of developing type 2 diabetes, chronic kidney disease, and cardiovascular disease. The incidence and prevalence of type 2 diabetes in the US adolescent population have increased in the last decade. Therefore, it is important to monitor the prevalenc...
Uložené v:
| Vydané v: | JAMA pediatrics Ročník 174; číslo 2; s. e194498 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.02.2020
|
| Predmet: | |
| ISSN: | 2168-6211, 2168-6211 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Individuals with prediabetes are at increased risk of developing type 2 diabetes, chronic kidney disease, and cardiovascular disease. The incidence and prevalence of type 2 diabetes in the US adolescent population have increased in the last decade. Therefore, it is important to monitor the prevalence of prediabetes and varying levels of glucose tolerance to assess the future risk of type 2 diabetes in the youngest segment of the population.
To examine the prevalence of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and increased glycated hemoglobin A1c (HbA1c) levels in US adolescents (aged 12-18 years) and young adults (aged 19-34 years) without diabetes.
This cross-sectional analyses of the 2005-2016 National Health and Nutrition Examination Survey assessed a population-based sample of adolescents and young adults who were not pregnant, did not have diabetes, and had measured fasting plasma glucose, 2-hour plasma glucose after a 75-g oral glucose tolerance test, and HbA1c levels. Analysis began in April 2017.
Impaired fasting glucose was defined as fasting plasma glucose of 100 mg/dL to less than 126 mg/dL, IGT as 2-hour plasma glucose of 140 mg/dL to less than 200 mg/dL, and increased HbA1c level as HbA1c level between 5.7% and 6.4%. The prevalence of IFG, isolated IFG, IGT, isolated IGT, increased HbA1c level, isolated increased HbA1c level, and prediabetes (defined as having IFG, IGT, or increased HbA1c level) were estimated. Fasting insulin levels and cardiometabolic risk factors across glycemic abnormality phenotypes were also compared. Obesity was defined as having age- and sex-specific body mass index (calculated as weight in kilograms divided by height in meters squared) in the 95th percentile or higher in adolescents or 30 or higher in young adults.
Of 5786 individuals, 2606 (45%) were adolescents and 3180 (55%) were young adults. Of adolescents, 50.6% (95% CI, 47.6%-53.6%) were boys, and 50.6% (95% CI, 48.8%-52.4%) of young adults were men. Among adolescents, the prevalence of prediabetes was 18.0% (95% CI, 16.0%-20.1%) and among young adults was 24.0% (95% CI, 22.0%-26.1%). Impaired fasting glucose constituted the largest proportion of prediabetes, with prevalence of 11.1% (95% CI, 9.5%-13.0%) in adolescents and 15.8% (95% CI, 14.0%-17.9%) in young adults. In multivariable logistic models including age, sex, race/ethnicity, and body mass index, the predictive marginal prevalence of prediabetes was significantly higher in male than in female individuals (22.5% [95% CI, 19.5%-25.4%] vs 13.4% [95% CI, 10.8%-16.5%] in adolescents and 29.1% [95% CI, 26.4%-32.1%] vs 18.8% [95% CI, 16.5%-21.3%] in young adults). Prediabetes prevalence was significantly higher in individuals with obesity than in those with normal weight (25.7% [95% CI, 20.0%-32.4%] vs 16.4% [95% CI, 14.3%-18.7%] in adolescents and 36.9% [95% CI, 32.9%-41.1%] vs 16.6% [95% CI, 14.2%-19.4%] in young adults). Compared with persons with normal glucose tolerance, adolescents and young adults with prediabetes had significantly higher non-high-density lipoprotein cholesterol levels, systolic blood pressure, central adiposity, and lower insulin sensitivity (P < .05 for all).
In the United States, about 1 of 5 adolescents and 1 of 4 young adults have prediabetes. The adjusted prevalence of prediabetes is higher in male individuals and in people with obesity. Adolescents and young adults with prediabetes also present an unfavorable cardiometabolic risk profile, putting them both at increased risk of type 2 diabetes and cardiovascular diseases. |
|---|---|
| AbstractList | Individuals with prediabetes are at increased risk of developing type 2 diabetes, chronic kidney disease, and cardiovascular disease. The incidence and prevalence of type 2 diabetes in the US adolescent population have increased in the last decade. Therefore, it is important to monitor the prevalence of prediabetes and varying levels of glucose tolerance to assess the future risk of type 2 diabetes in the youngest segment of the population.
To examine the prevalence of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and increased glycated hemoglobin A1c (HbA1c) levels in US adolescents (aged 12-18 years) and young adults (aged 19-34 years) without diabetes.
This cross-sectional analyses of the 2005-2016 National Health and Nutrition Examination Survey assessed a population-based sample of adolescents and young adults who were not pregnant, did not have diabetes, and had measured fasting plasma glucose, 2-hour plasma glucose after a 75-g oral glucose tolerance test, and HbA1c levels. Analysis began in April 2017.
Impaired fasting glucose was defined as fasting plasma glucose of 100 mg/dL to less than 126 mg/dL, IGT as 2-hour plasma glucose of 140 mg/dL to less than 200 mg/dL, and increased HbA1c level as HbA1c level between 5.7% and 6.4%. The prevalence of IFG, isolated IFG, IGT, isolated IGT, increased HbA1c level, isolated increased HbA1c level, and prediabetes (defined as having IFG, IGT, or increased HbA1c level) were estimated. Fasting insulin levels and cardiometabolic risk factors across glycemic abnormality phenotypes were also compared. Obesity was defined as having age- and sex-specific body mass index (calculated as weight in kilograms divided by height in meters squared) in the 95th percentile or higher in adolescents or 30 or higher in young adults.
Of 5786 individuals, 2606 (45%) were adolescents and 3180 (55%) were young adults. Of adolescents, 50.6% (95% CI, 47.6%-53.6%) were boys, and 50.6% (95% CI, 48.8%-52.4%) of young adults were men. Among adolescents, the prevalence of prediabetes was 18.0% (95% CI, 16.0%-20.1%) and among young adults was 24.0% (95% CI, 22.0%-26.1%). Impaired fasting glucose constituted the largest proportion of prediabetes, with prevalence of 11.1% (95% CI, 9.5%-13.0%) in adolescents and 15.8% (95% CI, 14.0%-17.9%) in young adults. In multivariable logistic models including age, sex, race/ethnicity, and body mass index, the predictive marginal prevalence of prediabetes was significantly higher in male than in female individuals (22.5% [95% CI, 19.5%-25.4%] vs 13.4% [95% CI, 10.8%-16.5%] in adolescents and 29.1% [95% CI, 26.4%-32.1%] vs 18.8% [95% CI, 16.5%-21.3%] in young adults). Prediabetes prevalence was significantly higher in individuals with obesity than in those with normal weight (25.7% [95% CI, 20.0%-32.4%] vs 16.4% [95% CI, 14.3%-18.7%] in adolescents and 36.9% [95% CI, 32.9%-41.1%] vs 16.6% [95% CI, 14.2%-19.4%] in young adults). Compared with persons with normal glucose tolerance, adolescents and young adults with prediabetes had significantly higher non-high-density lipoprotein cholesterol levels, systolic blood pressure, central adiposity, and lower insulin sensitivity (P < .05 for all).
In the United States, about 1 of 5 adolescents and 1 of 4 young adults have prediabetes. The adjusted prevalence of prediabetes is higher in male individuals and in people with obesity. Adolescents and young adults with prediabetes also present an unfavorable cardiometabolic risk profile, putting them both at increased risk of type 2 diabetes and cardiovascular diseases. Individuals with prediabetes are at increased risk of developing type 2 diabetes, chronic kidney disease, and cardiovascular disease. The incidence and prevalence of type 2 diabetes in the US adolescent population have increased in the last decade. Therefore, it is important to monitor the prevalence of prediabetes and varying levels of glucose tolerance to assess the future risk of type 2 diabetes in the youngest segment of the population.ImportanceIndividuals with prediabetes are at increased risk of developing type 2 diabetes, chronic kidney disease, and cardiovascular disease. The incidence and prevalence of type 2 diabetes in the US adolescent population have increased in the last decade. Therefore, it is important to monitor the prevalence of prediabetes and varying levels of glucose tolerance to assess the future risk of type 2 diabetes in the youngest segment of the population.To examine the prevalence of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and increased glycated hemoglobin A1c (HbA1c) levels in US adolescents (aged 12-18 years) and young adults (aged 19-34 years) without diabetes.ObjectiveTo examine the prevalence of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and increased glycated hemoglobin A1c (HbA1c) levels in US adolescents (aged 12-18 years) and young adults (aged 19-34 years) without diabetes.This cross-sectional analyses of the 2005-2016 National Health and Nutrition Examination Survey assessed a population-based sample of adolescents and young adults who were not pregnant, did not have diabetes, and had measured fasting plasma glucose, 2-hour plasma glucose after a 75-g oral glucose tolerance test, and HbA1c levels. Analysis began in April 2017.Design, Setting, and ParticipantsThis cross-sectional analyses of the 2005-2016 National Health and Nutrition Examination Survey assessed a population-based sample of adolescents and young adults who were not pregnant, did not have diabetes, and had measured fasting plasma glucose, 2-hour plasma glucose after a 75-g oral glucose tolerance test, and HbA1c levels. Analysis began in April 2017.Impaired fasting glucose was defined as fasting plasma glucose of 100 mg/dL to less than 126 mg/dL, IGT as 2-hour plasma glucose of 140 mg/dL to less than 200 mg/dL, and increased HbA1c level as HbA1c level between 5.7% and 6.4%. The prevalence of IFG, isolated IFG, IGT, isolated IGT, increased HbA1c level, isolated increased HbA1c level, and prediabetes (defined as having IFG, IGT, or increased HbA1c level) were estimated. Fasting insulin levels and cardiometabolic risk factors across glycemic abnormality phenotypes were also compared. Obesity was defined as having age- and sex-specific body mass index (calculated as weight in kilograms divided by height in meters squared) in the 95th percentile or higher in adolescents or 30 or higher in young adults.Main Outcomes and MeasuresImpaired fasting glucose was defined as fasting plasma glucose of 100 mg/dL to less than 126 mg/dL, IGT as 2-hour plasma glucose of 140 mg/dL to less than 200 mg/dL, and increased HbA1c level as HbA1c level between 5.7% and 6.4%. The prevalence of IFG, isolated IFG, IGT, isolated IGT, increased HbA1c level, isolated increased HbA1c level, and prediabetes (defined as having IFG, IGT, or increased HbA1c level) were estimated. Fasting insulin levels and cardiometabolic risk factors across glycemic abnormality phenotypes were also compared. Obesity was defined as having age- and sex-specific body mass index (calculated as weight in kilograms divided by height in meters squared) in the 95th percentile or higher in adolescents or 30 or higher in young adults.Of 5786 individuals, 2606 (45%) were adolescents and 3180 (55%) were young adults. Of adolescents, 50.6% (95% CI, 47.6%-53.6%) were boys, and 50.6% (95% CI, 48.8%-52.4%) of young adults were men. Among adolescents, the prevalence of prediabetes was 18.0% (95% CI, 16.0%-20.1%) and among young adults was 24.0% (95% CI, 22.0%-26.1%). Impaired fasting glucose constituted the largest proportion of prediabetes, with prevalence of 11.1% (95% CI, 9.5%-13.0%) in adolescents and 15.8% (95% CI, 14.0%-17.9%) in young adults. In multivariable logistic models including age, sex, race/ethnicity, and body mass index, the predictive marginal prevalence of prediabetes was significantly higher in male than in female individuals (22.5% [95% CI, 19.5%-25.4%] vs 13.4% [95% CI, 10.8%-16.5%] in adolescents and 29.1% [95% CI, 26.4%-32.1%] vs 18.8% [95% CI, 16.5%-21.3%] in young adults). Prediabetes prevalence was significantly higher in individuals with obesity than in those with normal weight (25.7% [95% CI, 20.0%-32.4%] vs 16.4% [95% CI, 14.3%-18.7%] in adolescents and 36.9% [95% CI, 32.9%-41.1%] vs 16.6% [95% CI, 14.2%-19.4%] in young adults). Compared with persons with normal glucose tolerance, adolescents and young adults with prediabetes had significantly higher non-high-density lipoprotein cholesterol levels, systolic blood pressure, central adiposity, and lower insulin sensitivity (P < .05 for all).ResultsOf 5786 individuals, 2606 (45%) were adolescents and 3180 (55%) were young adults. Of adolescents, 50.6% (95% CI, 47.6%-53.6%) were boys, and 50.6% (95% CI, 48.8%-52.4%) of young adults were men. Among adolescents, the prevalence of prediabetes was 18.0% (95% CI, 16.0%-20.1%) and among young adults was 24.0% (95% CI, 22.0%-26.1%). Impaired fasting glucose constituted the largest proportion of prediabetes, with prevalence of 11.1% (95% CI, 9.5%-13.0%) in adolescents and 15.8% (95% CI, 14.0%-17.9%) in young adults. In multivariable logistic models including age, sex, race/ethnicity, and body mass index, the predictive marginal prevalence of prediabetes was significantly higher in male than in female individuals (22.5% [95% CI, 19.5%-25.4%] vs 13.4% [95% CI, 10.8%-16.5%] in adolescents and 29.1% [95% CI, 26.4%-32.1%] vs 18.8% [95% CI, 16.5%-21.3%] in young adults). Prediabetes prevalence was significantly higher in individuals with obesity than in those with normal weight (25.7% [95% CI, 20.0%-32.4%] vs 16.4% [95% CI, 14.3%-18.7%] in adolescents and 36.9% [95% CI, 32.9%-41.1%] vs 16.6% [95% CI, 14.2%-19.4%] in young adults). Compared with persons with normal glucose tolerance, adolescents and young adults with prediabetes had significantly higher non-high-density lipoprotein cholesterol levels, systolic blood pressure, central adiposity, and lower insulin sensitivity (P < .05 for all).In the United States, about 1 of 5 adolescents and 1 of 4 young adults have prediabetes. The adjusted prevalence of prediabetes is higher in male individuals and in people with obesity. Adolescents and young adults with prediabetes also present an unfavorable cardiometabolic risk profile, putting them both at increased risk of type 2 diabetes and cardiovascular diseases.Conclusions and RelevanceIn the United States, about 1 of 5 adolescents and 1 of 4 young adults have prediabetes. The adjusted prevalence of prediabetes is higher in male individuals and in people with obesity. Adolescents and young adults with prediabetes also present an unfavorable cardiometabolic risk profile, putting them both at increased risk of type 2 diabetes and cardiovascular diseases. |
| Author | Cheng, Yiling J Andes, Linda J Imperatore, Giuseppina Rolka, Deborah B Gregg, Edward W |
| Author_xml | – sequence: 1 givenname: Linda J surname: Andes fullname: Andes, Linda J organization: National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia – sequence: 2 givenname: Yiling J surname: Cheng fullname: Cheng, Yiling J organization: National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia – sequence: 3 givenname: Deborah B surname: Rolka fullname: Rolka, Deborah B organization: National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia – sequence: 4 givenname: Edward W surname: Gregg fullname: Gregg, Edward W organization: Department of Public Health and Epidemiology, Imperial College London, London, United Kingdom – sequence: 5 givenname: Giuseppina surname: Imperatore fullname: Imperatore, Giuseppina organization: National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31790544$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUE1LAzEQDVKxtfYvSI4e3DpJk2xyLMUvKChoD4KwpJtZ3bKbrZus4L83aAXnMm8ebx5v5pSMfOeREMpgzgDY1c62do-utrGvyzDnwMxcCKOPyIQzpTPFGRv9w2MyC2EHqTSAWOQnZLxguQEpxIS8Pvb4aRv0JdKuomlKxluMGOiy7fwbXbquwVCij4Fa7-hLN_ywQ5OI2tP4jnTj64iOPkWb9i4pB5BZiqXOyHFlm4CzQ5-Szc318-ouWz_c3q-W68wKlcfMARjOtRPSuFJVonJS5RJLqapcV6YS4IwtNWMaLJQyYW63Ih3jEM0WJJ-Si1_ffd99DBhi0dYpctNYj90QCr7goHMucpWk5wfpsG3RFfu-bm3_Vfx9hH8DiG1naw |
| CitedBy_id | crossref_primary_10_1007_s10067_022_06093_3 crossref_primary_10_3390_sports8090121 crossref_primary_10_1016_j_jadohealth_2023_08_026 crossref_primary_10_1111_1753_0407_13301 crossref_primary_10_3390_medicina60091418 crossref_primary_10_1111_jdi_13226 crossref_primary_10_1111_cob_12504 crossref_primary_10_1111_pedi_13281 crossref_primary_10_3390_biomedicines8110478 crossref_primary_10_1016_j_pcl_2024_06_008 crossref_primary_10_3390_children8030172 crossref_primary_10_5409_wjcp_v13_i1_89201 crossref_primary_10_1186_s13098_022_00873_2 crossref_primary_10_1007_s42843_020_00014_1 crossref_primary_10_1080_19396368_2022_2033350 crossref_primary_10_1016_j_scitotenv_2022_154095 crossref_primary_10_2337_dci22_0034 crossref_primary_10_4239_wjd_v12_i12_2027 crossref_primary_10_5409_wjcp_v13_i4_97105 crossref_primary_10_1111_jspn_12351 crossref_primary_10_1002_oby_23974 crossref_primary_10_1111_obr_13513 crossref_primary_10_3389_fnut_2022_1007679 crossref_primary_10_1186_s13098_025_01662_3 crossref_primary_10_1073_pnas_2501723122 crossref_primary_10_1016_j_evalprogplan_2023_102305 crossref_primary_10_3390_nu14071369 crossref_primary_10_1016_j_socscimed_2023_115728 crossref_primary_10_1186_s12902_025_01890_8 crossref_primary_10_1016_j_metabol_2022_155238 crossref_primary_10_1097_MD_0000000000044462 crossref_primary_10_2337_dci22_0046 crossref_primary_10_3389_fendo_2020_531796 crossref_primary_10_1155_2022_4851044 crossref_primary_10_1210_clinem_dgab052 crossref_primary_10_1007_s00246_023_03141_w crossref_primary_10_1038_s41598_021_90406_0 crossref_primary_10_1007_s12519_022_00582_w crossref_primary_10_1007_s40618_022_01809_3 crossref_primary_10_1089_chi_2023_0110 crossref_primary_10_1210_clinem_dgaf099 crossref_primary_10_1007_s40618_023_02111_6 crossref_primary_10_1177_21501327211053750 crossref_primary_10_1001_jama_2025_10877 crossref_primary_10_12688_f1000research_132160_2 crossref_primary_10_12688_f1000research_132160_1 crossref_primary_10_1016_j_psychres_2023_115250 crossref_primary_10_1016_j_metop_2025_100345 crossref_primary_10_1542_peds_2022_057957 crossref_primary_10_1001_jamainternmed_2020_5938 crossref_primary_10_1007_s00198_021_06148_2 crossref_primary_10_3389_fpubh_2023_1200415 crossref_primary_10_1007_s00394_022_03078_5 crossref_primary_10_3390_ijerph18031328 crossref_primary_10_1007_s40615_024_01917_1 crossref_primary_10_1210_jendso_bvad118 crossref_primary_10_1007_s13679_021_00440_2 crossref_primary_10_3390_endocrines3030045 crossref_primary_10_2337_dc25_0343 crossref_primary_10_3390_children9081249 crossref_primary_10_1016_j_amepre_2021_12_009 crossref_primary_10_1038_s41598_024_84349_5 crossref_primary_10_1016_j_atherosclerosis_2023_117272 crossref_primary_10_1016_j_jacl_2025_04_182 crossref_primary_10_1016_j_anpedi_2022_05_005 crossref_primary_10_1177_1470320320963929 crossref_primary_10_1186_s12889_023_16580_0 crossref_primary_10_1111_dom_14237 crossref_primary_10_1055_s_0044_1800784 crossref_primary_10_1111_pedi_13083 crossref_primary_10_1001_jamanetworkopen_2024_35136 crossref_primary_10_1016_j_anpede_2022_05_006 crossref_primary_10_3390_ijerph192114601 crossref_primary_10_1111_ijpo_12699 crossref_primary_10_5114_amsad_2021_107820 crossref_primary_10_1007_s11892_023_01501_7 crossref_primary_10_1007_s40619_024_01417_8 crossref_primary_10_2196_53330 crossref_primary_10_1001_jama_2023_2307 crossref_primary_10_1016_j_numecd_2023_03_006 crossref_primary_10_1038_s41366_024_01465_y crossref_primary_10_1016_j_jneb_2023_10_003 crossref_primary_10_1001_jama_2022_14543 crossref_primary_10_1161_CIR_0000000000001052 crossref_primary_10_1097_FCH_0000000000000323 crossref_primary_10_3389_fendo_2023_1207045 crossref_primary_10_1016_j_jacl_2025_03_003 crossref_primary_10_18311_jnr_2025_49148 crossref_primary_10_3389_fped_2022_803323 crossref_primary_10_1155_2021_4350418 crossref_primary_10_2337_dc25_0001 crossref_primary_10_3390_biomedicines12061372 crossref_primary_10_1210_jendso_bvad014 crossref_primary_10_1155_jdr_6591307 crossref_primary_10_1155_pedi_9982025 crossref_primary_10_2337_dsi21_0013 crossref_primary_10_1002_oby_23643 crossref_primary_10_1161_HCQ_0000000000000120 crossref_primary_10_1152_advan_00088_2025 crossref_primary_10_1038_s41598_025_98777_4 crossref_primary_10_1123_jpah_2025_0022 crossref_primary_10_1210_clinem_dgae400 crossref_primary_10_3390_nu17060947 crossref_primary_10_1007_s13312_023_2941_y crossref_primary_10_1007_s13300_023_01455_9 crossref_primary_10_1186_s43162_024_00294_9 crossref_primary_10_1007_s11883_022_01024_8 crossref_primary_10_1111_pedi_13315 crossref_primary_10_1186_s12933_023_01776_w crossref_primary_10_7759_cureus_75542 crossref_primary_10_1186_s12902_024_01676_4 crossref_primary_10_1038_s41598_024_76183_6 crossref_primary_10_1007_s00125_022_05787_2 crossref_primary_10_1186_s12933_024_02516_4 crossref_primary_10_1016_S2213_8587_24_00316_4 crossref_primary_10_1210_clinem_dgaf040 crossref_primary_10_2147_DDDT_S462603 crossref_primary_10_1017_S1368980024000284 crossref_primary_10_4103_ijem_ijem_331_22 crossref_primary_10_1007_s11673_024_10405_4 crossref_primary_10_3889_oamjms_2022_8202 crossref_primary_10_1017_S0954579423000652 crossref_primary_10_1016_j_diabres_2023_110622 crossref_primary_10_1111_pedi_13206 crossref_primary_10_1001_jamainternmed_2021_4886 crossref_primary_10_1016_j_jadohealth_2020_12_003 crossref_primary_10_1007_s13679_025_00653_9 crossref_primary_10_3390_nu17101675 crossref_primary_10_3390_nu15143210 crossref_primary_10_1007_s12144_023_04453_z crossref_primary_10_1001_jamanetworkopen_2022_31196 crossref_primary_10_1016_j_ijcrp_2023_200202 crossref_primary_10_3390_nu17050797 crossref_primary_10_1001_jamapediatrics_2022_0077 crossref_primary_10_15829_1728_8800_2023_3393 crossref_primary_10_1038_s41598_025_07631_0 crossref_primary_10_3390_ijerph17176151 crossref_primary_10_1016_j_ajpc_2023_100582 crossref_primary_10_1161_CIRCRESAHA_123_322065 crossref_primary_10_3390_children10030516 crossref_primary_10_1177_13591053241243285 crossref_primary_10_3390_medicina61071190 crossref_primary_10_2337_dc21_0464 crossref_primary_10_1002_oby_23690 crossref_primary_10_1161_CIR_0000000000000950 crossref_primary_10_1016_j_envint_2022_107316 crossref_primary_10_4239_wjd_v15_i4_623 crossref_primary_10_1161_CIR_0000000000001123 crossref_primary_10_2196_25699 crossref_primary_10_3390_ijerph19159655 crossref_primary_10_1016_j_heliyon_2024_e25793 crossref_primary_10_1089_chi_2022_0209 crossref_primary_10_1001_jamanetworkopen_2024_16088 crossref_primary_10_1159_000528043 crossref_primary_10_1111_ijpo_12900 crossref_primary_10_1136_bmjopen_2024_086197 crossref_primary_10_3390_ijerph191912286 crossref_primary_10_1002_iub_2437 crossref_primary_10_1007_s11892_020_01328_6 crossref_primary_10_1016_j_jcjd_2021_01_011 crossref_primary_10_1186_s12933_020_01139_9 crossref_primary_10_1001_jama_2020_18731 crossref_primary_10_1080_09540091_2024_2325496 crossref_primary_10_2196_33082 crossref_primary_10_3389_fpubh_2022_923744 crossref_primary_10_1136_bmjdrc_2020_001981 crossref_primary_10_5888_pcd17_200050 crossref_primary_10_1016_j_jcte_2025_100414 crossref_primary_10_1016_j_diabres_2023_111022 crossref_primary_10_1210_jendso_bvae157 crossref_primary_10_3345_cep_2021_00213 crossref_primary_10_1080_09540105_2024_2398042 crossref_primary_10_1155_2024_6701192 crossref_primary_10_4239_wjd_v12_i4_344 crossref_primary_10_1001_jama_2023_4063 crossref_primary_10_1097_NMC_0000000000000844 crossref_primary_10_7759_cureus_53847 crossref_primary_10_1001_jamanetworkopen_2023_11466 crossref_primary_10_1002_dmrr_3828 crossref_primary_10_3390_nu14183734 crossref_primary_10_1016_j_cjca_2020_06_020 crossref_primary_10_1016_j_ctcp_2022_101659 crossref_primary_10_1016_j_heliyon_2023_e21286 crossref_primary_10_1111_pedi_13243 crossref_primary_10_1016_j_glmedi_2024_100119 crossref_primary_10_1186_s12966_022_01321_0 crossref_primary_10_1186_s12889_023_15122_y crossref_primary_10_3390_nu12123891 crossref_primary_10_1016_j_ijmedinf_2022_104960 crossref_primary_10_1161_JAHA_121_022857 crossref_primary_10_1542_peds_2022_060640 crossref_primary_10_1016_j_jacl_2025_05_020 crossref_primary_10_1515_jom_2020_0172 crossref_primary_10_3390_ijerph19010123 crossref_primary_10_1016_j_focus_2025_100378 crossref_primary_10_1016_S2352_4642_22_00278_4 crossref_primary_10_1007_s11886_021_01503_5 crossref_primary_10_1161_CIR_0000000000001209 crossref_primary_10_1016_j_hroo_2025_05_006 crossref_primary_10_2196_45561 crossref_primary_10_1210_clinem_dgac273 crossref_primary_10_1016_j_hsr_2025_100222 crossref_primary_10_1016_j_jacadv_2024_100867 crossref_primary_10_1016_j_eprac_2021_12_010 crossref_primary_10_1210_clinem_dgad124 crossref_primary_10_3390_ijerph20115961 crossref_primary_10_1210_jendso_bvad088 crossref_primary_10_1016_j_jacc_2021_05_004 crossref_primary_10_2147_DMSO_S284401 crossref_primary_10_18043_001c_117077 crossref_primary_10_1210_clinem_dgad482 crossref_primary_10_1007_s00395_022_00910_1 crossref_primary_10_1161_CIRCULATIONAHA_122_062624 crossref_primary_10_1186_s13063_020_04658_8 crossref_primary_10_1186_s12933_020_01052_1 crossref_primary_10_1016_j_pedhc_2020_10_005 crossref_primary_10_1249_FIT_0000000000001070 crossref_primary_10_3389_fpubh_2023_1181401 crossref_primary_10_1016_j_lana_2024_100699 crossref_primary_10_1097_XCE_0000000000000199 crossref_primary_10_3390_nu14173626 crossref_primary_10_3390_nu12040882 crossref_primary_10_1542_peds_2020_010272 crossref_primary_10_1016_j_healthplace_2025_103503 crossref_primary_10_3389_fendo_2022_916785 crossref_primary_10_1038_s41574_022_00669_4 crossref_primary_10_1155_2024_8333590 crossref_primary_10_1016_j_disamonth_2023_101582 crossref_primary_10_1017_S0029665122002804 crossref_primary_10_1161_CIR_0000000000001303 crossref_primary_10_1186_s12889_024_21061_z crossref_primary_10_1001_jamanetworkopen_2025_17455 crossref_primary_10_2337_dci24_0040 crossref_primary_10_1001_jama_2022_7957 crossref_primary_10_1080_07448481_2020_1819290 crossref_primary_10_1007_s00246_023_03139_4 crossref_primary_10_3390_antiox11071336 crossref_primary_10_1161_JAHA_120_020163 crossref_primary_10_1186_s13098_024_01491_w crossref_primary_10_1016_j_eprac_2023_04_010 crossref_primary_10_3390_nu14173614 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1001/jamapediatrics.2019.4498 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2168-6211 |
| ExternalDocumentID | 31790544 |
| Genre | Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GroupedDBID | 0R~ 4.4 53G AAWTL ABJNI ACGFS ACIWK ACPRK ADBBV AENEX AFOSN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU BRYMA C45 CGR CUY CVF EBD EBS ECM EIF EMOBN EX3 H13 HF~ NPM OB4 OBH OHH OVD PONUX PQQKQ RAJ SV3 TEORI WOW 7X8 |
| ID | FETCH-LOGICAL-a467t-d009228d459dc6f4fd5675ec56f78f9f40d9ac81180a0c59ac2ab4800dee9b052 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 263 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000512046100045&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2168-6211 |
| IngestDate | Wed Oct 01 14:29:59 EDT 2025 Thu Jan 02 22:57:38 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a467t-d009228d459dc6f4fd5675ec56f78f9f40d9ac81180a0c59ac2ab4800dee9b052 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://jamanetwork.com/journals/jamapediatrics/articlepdf/2755415/jamapediatrics_andes_2019_oi_190082.pdf |
| PMID | 31790544 |
| PQID | 2320872476 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2320872476 pubmed_primary_31790544 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-02-01 |
| PublicationDateYYYYMMDD | 2020-02-01 |
| PublicationDate_xml | – month: 02 year: 2020 text: 2020-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JAMA pediatrics |
| PublicationTitleAlternate | JAMA Pediatr |
| PublicationYear | 2020 |
| SSID | ssj0000800437 |
| Score | 2.6753027 |
| Snippet | Individuals with prediabetes are at increased risk of developing type 2 diabetes, chronic kidney disease, and cardiovascular disease. The incidence and... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | e194498 |
| SubjectTerms | Adolescent Adult Blood Glucose - analysis Child Cross-Sectional Studies Diabetes Mellitus, Type 2 - epidemiology Female Glucose Intolerance - blood Glycated Hemoglobin A - analysis Humans Male Prediabetic State - blood Prediabetic State - epidemiology Prevalence Risk Assessment Time Factors United States - epidemiology Young Adult |
| Title | Prevalence of Prediabetes Among Adolescents and Young Adults in the United States, 2005-2016 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31790544 https://www.proquest.com/docview/2320872476 |
| Volume | 174 |
| WOSCitedRecordID | wos000512046100045&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFB7UinhxX-rGCB4dTdJZT1LE4qWlB4UehDCZBQqSVNv6-30zSexJELyEZGAgefPy5nvLfA-hG6a1D9saSbXg4KAkluieSAl3iiaGOi0SE5tNiNFITiZq3ATc5k1ZZWsTo6G2lQkx8nvY-RMpMir4w-yDhK5RIbvatNBYR50eQJmg1WIif2IsAQ3RSJuZpVwSDs5OU8zTEg_N2n4Ygbk7VXeUKvk71ox7zmD3v2-7h3YatIn7tXrsozVXHqCtYZNPP0RvgcFJx3NHuPIYntpYLO6HLkS4vyJ8wrq0OBoHGF2-w8C0xAAfcQ1bcQ1bb3FkHYXP5EfodfD08vhMmn4LRMNqLYgNBEyZtJQpa7in3jJwJ5xh3AvplaeJVdrIQBqnE8PgPtMFBRlb51SRsOwYbZRV6U4RFrrQQmXSeWXDuenCKO19amEmZdKyLrpu5ZaDPockhS5dtZznK8l10Ukt_HxWE2_kvUgnRunZH2afo-0suMaxwPoCdTz8ze4SbZqvxXT-eRUVBa6j8fAbaNjGtA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevalence+of+Prediabetes+Among+Adolescents+and+Young+Adults+in+the+United+States%2C+2005-2016&rft.jtitle=JAMA+pediatrics&rft.au=Andes%2C+Linda+J&rft.au=Cheng%2C+Yiling+J&rft.au=Rolka%2C+Deborah+B&rft.au=Gregg%2C+Edward+W&rft.date=2020-02-01&rft.eissn=2168-6211&rft.volume=174&rft.issue=2&rft.spage=e194498&rft_id=info:doi/10.1001%2Fjamapediatrics.2019.4498&rft_id=info%3Apmid%2F31790544&rft_id=info%3Apmid%2F31790544&rft.externalDocID=31790544 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2168-6211&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2168-6211&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2168-6211&client=summon |